

IN THE CLAIMS

1-10 (Canceled).

11. (Previously Presented) The method according to Claim 20, wherein the guanyldrazone-substituted compound is CNI-1493.

12. (Canceled).

13. (Previously Presented) The method according to Claim 11, wherein the disease or disorder is modulated by inhibiting signaling along a pathway within the cascade.

14. (Previously Presented) The method according to Claim 11, further comprising administering an additional therapeutic agent.

15. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is an anti-viral agent.

16. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is a reverse transcriptase inhibitor.

17. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is an HIV protease inhibitor.

18. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is a preintegration complex inhibitor.

19. (Previously Presented) The method according to Claim 20, wherein the disease or disorder is modulated by inhibiting signaling along a pathway through p38 MAP kinase within the cascade.

20. (Previously Presented) A method for treating HIV, comprising administering an effective HIV-treating amount of a guanyldiazone-substituted compound to a subject known to have HIV.